analysts and calls -- ML Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- ML

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	3/9/2006 7:54:54 AM
	of 238

This is from 3/3, missed it when it came out, sorry: CELG Price Target Changes Celgene Corporation (CELG, $39.37, C-1-9) Reiterate Buy. Raising PT to $49 from $39, as We Increased our '06-'10 EPS CAGR to 39% from 34% Based on Higher Revlimid ests. Raised our U.S. Revlimid (multiple myeloma) sales ests to $849 MM from $762 MM in '08, to $1.08 BB from $930 MM in '09, & to $1.26 BB from $1.12 BB in '10. Lots of leverage in CELG’s P&L (e.g., Revlimid’s > $50K/year pricing & 95% gross margin). More upside potential may come from other indications, & for Thalomid. We expect the FDA to grant 6-mo. priority review for Revlimid’s supplemental NDA in multiple myeloma and look for approval of an expanded label in June.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next